Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

Alzheimer's & Dementia : Translational Research & Clinical Interventions
Adam J SchwarzEric R Siemers

Abstract

Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy as measured by volumetric magnetic resonance imaging (MRI). In the EXPEDITION3 phase 3 trial, participants with mild Alzheimer's disease were randomized to receive intravenous infusions of either 400 mg of solanezumab or placebo every 4 weeks for 76 weeks. Volumetric MRI scans were acquired at baseline and at 80 weeks from 275 MRI facilities using a standardized imaging protocol. A subset of 1462 patients who completed both MRI and 14-item Alzheimer's Disease Assessment Scale-Cognitive Subscale assessments at both time points were selected for analysis. Longitudinal MRI volume changes were analyzed centrally by tensor-based morphometry with a standard FreeSurfer brain parcellation. Prespecified volumetric measures, including whole brain and ventricles, along with anatomically localized regions in the temporal, parietal, and frontal lobes were evaluated in those participants. Group-mean differences in brain atrophy rates were directionally consist...Continue Reading

References

Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Jul 5, 2001·Proceedings of the National Academy of Sciences of the United States of America·R B DeMattosD M Holtzman
May 11, 2005·Neurology·N C FoxUNKNOWN AN1792(QS-21)-201 Study
Mar 14, 2007·Brain : a Journal of Neurology·An-Tao DuMichael W Weiner
Dec 26, 2008·Neurology·Akram BakkourBradford C Dickerson
May 11, 2010·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Laurel A BeckettUNKNOWN Alzheimer's Disease Neuroimaging Initiative
May 18, 2010·Neurobiology of Aging·Carrie R McDonaldUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jun 22, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·Bradford C DickersonUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Aug 10, 2011·Archives of Neurology·Mert R SabuncuUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Aug 11, 2011·Human Brain Mapping·Dominic HollandUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jan 24, 2014·The New England Journal of Medicine·Rachelle S DoodyUNKNOWN Solanezumab Study Group
Jan 24, 2014·The New England Journal of Medicine·Stephen SallowayUNKNOWN Bapineuzumab 301 and 302 Clinical Trial Investigators
Aug 5, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Eric R SiemersRonald Demattos
May 11, 2016·Journal of Alzheimer's Disease : JAD·Alberto RussuChuanpu Hu
May 14, 2016·Alzheimer's Research & Therapy·Rik VandenbergheUNKNOWN Bapineuzumab 3000 and 3001 Clinical Study Investigators
Apr 6, 2017·BMC Neurology·Abdelrahman Ibrahim AbushoukAmmar M AlSafadi
Jan 25, 2018·The New England Journal of Medicine·Lawrence S HonigEric Siemers

❮ Previous
Next ❯

Citations

Feb 11, 2020·Current Opinion in Psychiatry·Júlia C LoureiroLeonardo Cruz de Souza
Aug 11, 2020·Expert Opinion on Emerging Drugs·Madia LozuponeFrancesco Panza
Jan 17, 2021·European Radiology·Hugh G PembertonUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 14, 2020·Journal of Central Nervous System Disease·Konstantina G Yiannopoulou, Sokratis G Papageorgiou
Apr 14, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Adam J Schwarz
May 8, 2021·Molecular Neurodegeneration·Yona LevitesTodd E Golde
Jun 5, 2021·Brain Communications·Clément Abi NaderUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Oct 6, 2021·Journal of Neurology·Joseph Pleen, Ryan Townley

❮ Previous
Next ❯

Software Mentioned

FreeSurfer

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Related Papers

The New England Journal of Medicine
Rachelle DoodySolanezumab Study Group
The New England Journal of Medicine
Lawrence S HonigEric R Siemers
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Christopher CarlsonJerome Barakos
© 2021 Meta ULC. All rights reserved